IFITM1
(Interferon-Induced Transmembrane Protein 1 (IFITM1))
蛋白类型
Recombinant
产品特性
AA 1-125
宿主
人
资源
HEK-293 Cells
标记
This IFITM1 protein is labelled with His tag.
原理
Made-to-order recombinant IFITM1 Protein expressed in mammalian cells.
序列
MHKEEHEVAV LGPPPSTILP RSTVINIHSE TSVPDHVVWS LFNTLFLNWC CLGFIAFAYS VKSRDRKMVG DVTGAQAYAS TAKCLNIWAL ILGILMTIGF ILLLVFGSVT VYHIMLQIIQ EKRGY Sequence without tag. The proposed Purification-Tag is based on experiences with the expression system, a different complexity of the protein could make another tag necessary. In case you have a special request, please contact us.
特异性
If you are looking for a specific domain and are interested in a partial protein or a different isoform, please contact us regarding an individual offer.
产品特性
Key Benefits:
Made to order protein - from design to production - by highly experienced protein experts.
Protein expressed in mammalian cells and purified in one-step affinity chromatography
The optimized expression system ensures reliability for intracellular, secreted and transmembrane proteins.
State-of-the-art algorithm used for plasmid design (Gene synthesis).
This protein is a made-to-order protein and will be made for the first time for your order. Our experts in the lab try to ensure that you receive soluble protein.
If you are not interested in a full length protein, please contact us for individual protein fragments.
The big advantage of ordering our made-to-order proteins in comparison to ordering custom made proteins from other companies is that there is no financial obligation in case the protein cannot be expressed or purified.
纯度
> 90 % as determined by Bis-Tris PAGE, anti-tag ELISA, Western Blot and analytical SEC (HPLC)
custom-made
IFITM1
宿主: 人
宿主: Cell-free protein synthesis (CFPS)
Recombinant
> 70-80 % as determined by SDS PAGE, Western Blot and analytical SEC (HPLC).
ELISA, WB, SDS
custom-made
IFITM1
宿主: 小鼠
宿主: Cell-free protein synthesis (CFPS)
Recombinant
> 70-80 % as determined by SDS PAGE, Western Blot and analytical SEC (HPLC).
ELISA, WB, SDS
IFITM1
宿主: 人
宿主: HEK-293 Cells
Recombinant
> 80 % as determined by SDS-PAGE and Coomassie blue staining
AbP, STD
应用备注
We expect the protein to work for functional studies. As the protein has not been tested for functional studies yet we cannot offer a guarantee though.
限制
仅限研究用
状态
Liquid
缓冲液
The buffer composition is at the discretion of the manufacturer.
注意事项
Avoid repeated freeze-thaw cycles.
储存条件
-80 °C
储存方法
Store at -80°C.
有效期
12 months
抗原
IFITM1
(Interferon-Induced Transmembrane Protein 1 (IFITM1))
Interferon-induced transmembrane protein 1 (Dispanin subfamily A member 2a) (DSPA2a) (Interferon-induced protein 17) (Interferon-inducible protein 9-27) (Leu-13 antigen) (CD antigen CD225),FUNCTION: IFN-induced antiviral protein which inhibits the entry of viruses to the host cell cytoplasm, permitting endocytosis, but preventing subsequent viral fusion and release of viral contents into the cytosol. Active against multiple viruses, including influenza A virus, SARS coronaviruses (SARS-CoV and SARS-CoV-2), Marburg virus (MARV), Ebola virus (EBOV), Dengue virus (DNV), West Nile virus (WNV), human immunodeficiency virus type 1 (HIV-1) and hepatitis C virus (HCV) (PubMed:26354436, PubMed:33270927). Can inhibit: influenza virus hemagglutinin protein-mediated viral entry, MARV and EBOV GP1,2-mediated viral entry and SARS-CoV and SARS-CoV-2 S protein-mediated viral entry. Also implicated in cell adhesion and control of cell growth and migration (PubMed:33270927). Inhibits SARS-CoV-2 S protein-mediated syncytia formation (PubMed:33051876). Plays a key role in the antiproliferative action of IFN-gamma either by inhibiting the ERK activation or by arresting cell growth in G1 phase in a p53-dependent manner. Acts as a positive regulator of osteoblast differentiation. In hepatocytes, IFITM proteins act in a coordinated manner to restrict HCV infection by targeting the endocytosed HCV virion for lysosomal degradation (PubMed:26354436). IFITM2 and IFITM3 display anti-HCV activity that may complement the anti-HCV activity of IFITM1 by inhibiting the late stages of HCV entry, possibly in a coordinated manner by trapping the virion in the endosomal pathway and targeting it for degradation at the lysosome (PubMed:26354436). {ECO:0000269|PubMed:16847454, ECO:0000269|PubMed:20064371, ECO:0000269|PubMed:20838853, ECO:0000269|PubMed:21177806, ECO:0000269|PubMed:21253575, ECO:0000269|PubMed:21976647, ECO:0000269|PubMed:22479637, ECO:0000269|PubMed:22634173, ECO:0000269|PubMed:26354436, ECO:0000269|PubMed:33051876, ECO:0000269|PubMed:33270927}.